Roman Yelensky

USPTO Granted Patents = 31 (Patent Applications = 49)

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 330(Granted Patents)

Company Filing History:

24 out of 39

Foundation Medicine, Inc.

Gritstone Oncology, Inc.

Vanderbilt University

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12456541 - Analysis of genetic variants (2025-10-28),

2. 12378302 - Fusion molecules and uses thereof (2025-08-05),

3. 12331128 - Therapeutic and diagnostic methods for cancer (2025-06-17),

4. 12180540 - Optimization of multigene analysis of tumor samples (2024-12-31),

5. 12116638 - Estrogen receptor mutations and uses thereof (2024-10-15),

6. 11885815 - Reducing junction epitope presentation for neoantigens (2024-01-30),

7. 11771747 - Multiepitope vaccine cassettes (2023-10-03),

8. 11766439 - Human papilloma virus as predictor of cancer prognosis (2023-09-26),

9. 11725247 - Methods of treating cancer (2023-08-15),

10. 11421265 - Optimization of multigene analysis of tumor samples (2022-08-23),

11. 11300570 - Therapeutic and diagnostic methods for cancer (2022-04-12),

12. 11286532 - Estrogen receptor mutations and uses thereof (2022-03-29),

13. 11279767 - Therapeutic and diagnostic methods for cancer (2022-03-22),

14. 11264117 - Neoantigen identification using hotspots (2022-03-01),

15. 11230589 - Fusion molecules and uses thereof (2022-01-25),

Title: The Innovative Contributions of Roman Yelensky in Oncology

Introduction

Roman Yelensky is an accomplished inventor and researcher based in Newton, MA, with an impressive portfolio of 28 patents. His work primarily focuses on the field of oncology, particularly in the analysis and treatment of tumors, making significant strides in medical research and innovation.

Latest Patents

Among his latest innovations, Yelensky has developed groundbreaking methods related to tumor analysis. One notable patent is an optimization technique for multigene analysis of tumor samples, which enhances the understanding of cancer genomics. Additionally, he has disclosed novel mutant Estrogen Receptor 1 (ESR1) molecules and their uses, indicating forward-thinking applications in targeted cancer therapies.

Career Highlights

Throughout his career, Yelensky has worked with prestigious companies that are leaders in the field of genomic medicine. He has been associated with Foundation Medicine, Inc., a company known for its advanced genomic profiling technologies, and UCL Business Plc, which connects university research with commercial enterprise. His contributions at these organizations have been pivotal in advancing personalized medicine.

Collaborations

Yelensky has collaborated with esteemed colleagues such as Philip James Stephens and Garrett Michael Frampton. Their collective expertise fosters a dynamic research environment that promotes innovative solutions in cancer treatment and diagnostics.

Conclusion

Roman Yelensky's contributions to the medical field, particularly in oncology, highlight the importance of innovation in health care. His patents not only represent personal achievement but also serve as a foundation for future advancements in cancer research, ultimately aiming to improve patient outcomes and treatment strategies.

This text is generated by artificial intelligence and may not be accurate.